Omkar Speciality Chemicals has applied for the patent of an intermediate drug for Hepatitis C. In an interview to CNBC-TV18, whole time director Omkar P Herlekar, says the drug, once it is granted a patent, will be able to contribute 15-20 percent to the company’s FY17 topline.
Furthermore, Herlekar is confident of growing more than industry standards for FY16.
Transcript to follow soon.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
